RBOT 8-K
Vicarious Surgical Inc. (RBOT)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including
area code: (
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01. Regulation FD Disclosure.
As of September 8, 2025, Vicarious Surgical Inc. (the “Company”) updated its investor presentation (the “Presentation”), which its senior management intends to use from time to time when interacting with investors and analysts, among others, including at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8-10, 2025, at the Lotte New York Palace Hotel in New York City, at which Stephen From, Chief Executive Officer of the Company, will be presenting at approximately 9:00 a.m. Eastern Time on September 10, 2025. The Presentation is available on the Company’s website at https://investor.vicarioussurgical.com/events-and-presentations/. A copy of the Presentation is also furnished hereto as Exhibit 99.1.
The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
| (d) | Exhibits. |
| Exhibit No. | Description | |
| 99.1 | Investor Presentation | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| VICARIOUS SURGICAL INC. | ||
| By: | /s/ Stephen From | |
| Name: | Stephen From | |
| Title: | Chief Executive Officer | |
Date: September 8, 2025
2
Exhibit 99.1
Transforming Surgery: Open - like Access, Minimally Invasive
Vicarious Surgical LEGAL DISCLAIMERS This presentation includes “forward - looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Vicarious Surgical’s actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward - looking statements as predictions of future events. All statements other than statements of historical facts contained herein, including without limitation, expected development timelines, estimated total addressable market, the potential benefits of the Vicarious Surgical System compared to existing alternatives, and potential indications, are forward - looking statements that reflect the current beliefs and expectations of management. These forward - looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward - looking statements. Most of these factors are outside Vicarious Surgical’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the ability to maintain the listing of Vicarious Surgical’s Class A common stock on the New York Stock Exchange; the approval, commercialization and adoption of Vicarious Surgical’s initial product candidates and the success of its single - port surgical robot, called the Vicarious Surgical System, and any of its future product candidates and service offerings; changes in applicable laws or regulations; the ability of Vicarious Surgical to raise financing in the future; the success, cost and timing of Vicarious Surgical’s product and service development activities; the potential attributes and benefits of Vicarious Surgical’s product candidates and services; Vicarious Surgical’s ability to obtain and maintain regulatory approval for the Vicarious Surgical System, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for the Vicarious Surgical System; Vicarious Surgical’s ability to identify, in - license or acquire additional technology; Vicarious Surgical’s ability to maintain its existing license, manufacture, supply and distribution agreements; Vicarious Surgical’s ability to compete with other companies currently marketing or engaged in the development of products and services that Vicarious Surgical is currently marketing or developing; the size and growth potential of the markets for Vicarious Surgical’s product candidates and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of Vicarious Surgical’s product candidates and services and reimbursement for medical procedures conducted using its product candidates and services; the company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; Vicarious Surgical’s financial performance; economic downturns, political and market conditions and their potential to adversely affect Vicarious Surgical’s business, financial condition and results of operations; Vicarious Surgical’s intellectual property rights and its ability to protect or enforce those rights, and the impact on its business, results and financial condition if it is unsuccessful in doing so; and other risks and uncertainties indicated from time to time in Vicarious Surgical’s filings with the Securities and Exchange Commission. Vicarious Surgical cautions that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward - looking statements, which speak only as of the date made. Vicarious Surgical does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward - looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. All surgical images contained in this presentation are sourced from cadaveric procedures.
Vicarious Surgical Minimally Invasive Surgery Small incisions, but limited anatomical access, visualization and reach, especially in the abdomen. Open Surgery Full anatomical access, but high complications and difficult recovery. Today, Surgeons Choose Between Anatomical Access & Invasiveness Result: Many abdominal surgeries are still performed open, despite the known and agreed upon benefits of MIS. “We eliminate the tradeoff: open - surgery experience through a single incision.”
Vicarious Surgical Legacy Robot Adoption is Heavily Concentrated in Prostatectomy Not By Design, But By Limitation Current Robotics: Prostatectomy: Built as a General - Purpose System Multi - port entry, rigid arms, and limited freedom of motion. One size fits all approach. The Dominant Robotic Procedure >95% adoption rate Confined pelvic anatomy aligns with robot’s strengths: ● Operates well in a small, narrow space ● Straightforward setup & triangulation ● Stable visualization ● Tremor reduction There is massive upside in procedures that don’t fit existing systems.
Vicarious Surgical High Adoption: Anatomy Fits Current Robot Strengths Low Adoption: Anatomy Requires Open - Like Dexterity Beyond Prostatectomy: Adoption Drops Sharply Hernia repair, cholecystectomy, hysterectomy, and stomach/intestinal procedures require broad maneuverability, complex suturing and multi - quadrant access. These indications remain largely non - robotic (>82% 1 ) 1 VS ESTIMATES FROM 2022 LSI GLOBAL MARKET DATA Cholecystectomy Ventral Hernia Hysterectomy - Ben. Inguinal Hernia Colorectal Foregut Bariatrics Hysterectomy - Malig Prostatectomy Other Thoracic 5% 17% 23% 34% 5 % 17% 46% 35% 100% 13% Robotic Open & Laparoscopic Data collected from a center of excellence partner hospital system. % of volume of procedures
Vicarious Surgical One Small Incision. Unlimited Access. Open Surgery Access — Through a Single, Small Incision Current Robotic Systems Vicarious Surgical “We are redefining robotic surgery — expanding access to millions of procedures beyond the reach of today’s systems.” Prostate Prostate
Vicarious Surgical The World’s Most Advanced Surgical Robot — Designed to Bring Open - Like Access & Perspective in Abdominal Procedures Surgeon Empowered Natural motion and full anatomical reach for open - like surgery. Hospital Advantage New revenue streams, improved economics, scalable adoption. Future Ready Data - rich platform will enable AI automation.
Vicarious Surgical One Small Incision. Unlimited Access. Open Surgery Access — Through the Smallest Incision 360 ƒ camera articulation with 120 ƒ field of view provides expanded visualization of the operative field & self cleaning . Decoupled actuators enable additional intra - abdominal joints with advanced dexterity and anatomical reach. Instrument arms generate high forces needed for a broad range of soft - tissue indications . “We are redefining robotic surgery — expanding access to millions of procedures beyond the reach of today’s systems.”
Vicarious Surgical We Are Launching in Ventral Hernia Repair Starting Where Others Can’t Go: Redefining Abdominal Access With the ability to work up, down and even backwards, Vicarious Surgical can reach areas of the abdominal wall that are currently difficult or even impossible with other systems . The anterior abdominal wall is a conundrum for “straight”, rigid technology and as a result 54 % of all Ventral Hernias in the U . S . are still performed open . Vicarious Surgical’s unique capabilities may lead to better patient outcomes and operational efficiency in a procedure where it matters most. “We are redefining robotic surgery — expanding access to millions of procedures beyond the reach of today’s systems.”
Vicarious Surgical 5.6 Million abdominal procedures performed annually in the US 1 We Are Addressing Procedures That Are Not Currently Being Done with Today’s Robotics Vicarious Surgical is expanding the TAM for robotic surgery, not fighting for a slice of the current pie. 82% are still non - robotic. Indications: Hernia, Gallbladder, GI, Gynecology. Why: ڶ Current robotics: limited anatomical access with a steep learning curve ڶ Vast majority of these procedures are still performed open, leading to a large white - space opportunity 82% 18% 1 VS ESTIMATES FROM 2021 - 2024 LSI GLOBAL MARKET DATA AND 2019 BANK OF AMERICA GLOBAL MARKET RESEARCH .
Vicarious Surgical Vicarious Surgical is Positioned for a Different TAM 82% Non - Robotic (US abdominal procedures market 1 ) 18% Robot - Assisted 2 1 INCLUDES HERNIA, GALLBLADDER, GI, AND GYNECOLOGICAL PROCEDURES. 2 VS ESTIMATES FROM 2021 - 2024 LSI GLOBAL MARKET DATA AND 2019 BANK OF AMERICA GLOBAL MARKET RESEARCH
Vicarious Surgical Our Proprietary Technology is Secured By A Comprehensive IP Portfolio Covering All Major System Innovations 1 Single Port Insertion 9 DOF Instruments 360 ƒ Visualization Decoupled Actuators 18 37 39 17 Camera Surgeon Intra - abd. AI & cleaning Interface motion Automation 5 21 38 15 Ensures Freedom to Operate and Long - Term Competitive Moat. 43 granted/allowed patents 87 pending 130 total protections filed 1 PATENT APPLICATIONS MAY CLAIM MORE THAN ONE FEATURE.
Vicarious Surgical Trusted by Leading Visionary Investors Visionary investors share our belief: Vicarious Surgical will expand robotic surgery into millions of new procedures. Backed by the world’s most forward thinking investors. Leading strategic investors validate Vicarious Surgical’s vision of expanding the future of robotic surgery and advancing minimally invasive care. BILL GATES
Transitioning from Discovery to Design Lock Commercial Readiness
Vicarious Surgical Major Milestone: First Build Under Control ● Completed under control, where every subsystem, every part, and every assembly step were documented, traceable, and auditable ● A clear transition point in maturity of the organization ● Parts assembled in a manner that can scale into manufacturing Vicarious Surgical achieved one of the most important milestones in the development of our robotic surgical platform Apr/2025
Vicarious Surgical August 2025: Efficiency Proof Point Second build demonstrated scalability & reproducibility. ● Same requirements, rebuilt faster and more efficiently ● Demonstrated ability to repeat build under control ● Confidence in scalability of platform integration ● We stressed the platform in a controlled environment, captured insights into stability and reliability, and identified where refinements were needed. Apr/25 Aug/25
Vicarious Surgical Current Progress Apr/25 Steady incorporation of remaining requirements. Aug/25 Sept/25 ● Team has been focused on incorporating the remaining design requirements into the system ● From mid - June to September, we’ve progressed from 49% to 63% functionality ● Clear trajectory toward 100%
Vicarious Surgical Next Major Milestone: Production Equivalent System Apr/25 Production - Equivalent System Aug/25 Sept/25 Mid/26 ● Will mark a true inflection point in our development program ● Will serve as the basis for manufacturing, clinical use, and ultimately commercialization ● This milestone will bring us to the system that matters most: a production - equivalent platform that will advance through design lock and into clinic
Vicarious Surgical Major Inflection Point: Design Lock Apr/25 Design lock = end of Discovery, start of Regulatory V&V Aug/25 Sept/25 Mid/26 Yr - End/26 ● All Design Requirements frozen ● Multiple builds under control → hardened, stable system ● Ready to advance into Regulatory V&V and clinic ● Has been hardened through multiple cycles of controlled integration
Vicarious Surgical Proven Leadership: The Expertise to Execute Hardware Lisa Futato Software Todd Storch Electrical David Bonyuet Operations Mike Varieur Clinical & Regulatory Mike Tricoli Quality Jai Paul Program Management Jay Therriault Commercial Edaun Pickholz
Vicarious Surgical: Bringing An Open - Surgery Experience to Robotics Join Us In Transforming Surgery For Millions Of Patients Worldwide Vicarious Surgical 78 Fourth Avenue Waltham, MA 02451 US [email protected] Vicarious Surgical